Abstract Number: 0162 • ACR Convergence 2025
Clinical Relevance of Systematic Comorbidity Screening in Autoimmune and Inflammatory Diseases
Background/Purpose: Chronic autoimmune and inflammatory diseases are associated with an increased prevalence of various comorbidities, which may impact both prognosis and therapeutic strategies. EULAR recommends…Abstract Number: 2594 • ACR Convergence 2025
Comparing Immunogenicity Between TVB-009 and Reference Denosumab in Healthy Adults and Participants with Postmenopausal Osteoporosis
Background/Purpose: TVB-009 is being developed as a proposed biosimilar candidate to the reference denosumab. Denosumab is a human IgG2 monoclonal antibody that binds to the…Abstract Number: 2108 • ACR Convergence 2025
Multidisciplinary Fragility Fracture Management Across Two Coordinated Hospitals: Evaluating Risk Factors, Treatment Approaches, and Long-Term Patient Outcomes in Those With and Without Prior Fractures
Background/Purpose: Our Fracture Coordination Unit operates across two hospitals: University Hospital of Donostia (UHD) and Matía Hospital (MH). Patients with a geriatric profile are transferred…Abstract Number: 0352 • ACR Convergence 2025
Complication Rates of Typical Hip Fractures, Subtrochanteric Femoral Fractures, and Atypical Femoral Fractures
Background/Purpose: Atypical femoral fractures (AFFs) are a rare complication of bisphosphonate use and a major reason that drug holidays are recommended following bisphosphonate use. However,…Abstract Number: 0149 • ACR Convergence 2025
Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have a 2-fold increase in risk for osteoporosis compared to the general population. About 30-50% of RA patients experience…Abstract Number: 2592 • ACR Convergence 2025
Romosozumab and Denosumab Combination Therapy in Postmenopausal Osteoporosis
Background/Purpose: Transition from long-term denosumab to PTH-analogs or romosozumab might expose patients to the risk of the so-called rebound phenomenon. Adding romosozumab to denosumab might…Abstract Number: 2107 • ACR Convergence 2025
Experience of a Fragility Fracture Coordination Unit Integrated Across Two Hospitals: An Innovative Multidisciplinary Model for Optimizing the Management of Geriatric and Non-Geriatric Patients Beyond Surgery After an Osteoporotic Bone Fragility Fracture
Background/Purpose: Fracture Coordination Units typically function within a single hospital using a multidisciplinary approach. Our unit, established in February 2024, pioneers a model coordinating care…Abstract Number: 0350 • ACR Convergence 2025
Perioperative Evaluation of Blood Tests Including Bone Turnover Markers in Patients Undergoing Surgery for Proximal Femur Fractures
Background/Purpose: Osteoporosis treatment is essential to prevent fractures. However, few patients with proximal femur fractures receive osteoporosis treatment before injury. Initiating treatment postoperatively is critical…Abstract Number: 0064 • ACR Convergence 2025
Sclerostin from marrow adipogenic precursors is essential for bone and joint homeostasis in mice
Background/Purpose: A novel mesenchymal subpopulation known as 'marrow adipogenic lineage precursors' (MALPs) has been identified, characterized by the expression of various adipocyte markers while lacking…Abstract Number: 2591 • ACR Convergence 2025
Association Between Changes in Bone Quality Parameters and Inflammatory Ratios in Postmenopausal Women Treated With Romosozumab: A Retrospective Observational Study
Background/Purpose: Osteoporosis (OP) is characterized by low bone mass and microarchitectural deterioration, increasing fracture risk. Bone Mineral Density (BMD), T-score, and Trabecular Bone Score (TBS)…Abstract Number: 2106 • ACR Convergence 2025
Prevalence and Characteristics of Morphometric Vertebral Fractures in the Spanish Population: Data from the OsteoSER Study
Background/Purpose: Most vertebral fractures (VFs) are asymptomatic. Vertebral Fracture Assessment (VFA) using DXA is a low-radiation method to detect morphometric vertebral fractures (MVFs). This study…Abstract Number: 0351 • ACR Convergence 2025
Experience with romosozumab in women with osteoporosis at high risk of fracture in real-world clinical practice
Background/Purpose: Romosozumab (RMZ) is a recently approved dual-acting drug which has been shown to reduce fracture risk in patients with osteoporosis (OP) in clinical trials.…Abstract Number: 2114 • ACR Convergence 2025
Development of a Fracture Prediction Model for Patients Aging with HIV
Background/Purpose: Fragility fractures are a critical outcome for people ageing with HIV (PAH). Studies demonstrate higher prevalence, incidence, and earlier onset than for the general…Abstract Number: 2566 • ACR Convergence 2025
Using Abdominal CT-Derived Bone Mineral Density and Psoas Volume for Opportunistic Osteoporosis Screening and Fracture Risk Assessment
Background/Purpose: Osteoporosis (OP) is assessed by dual-energy X-ray absorptiometry (DXA) for bone mineral density (BMD). Computed tomography (CT) offers an alternative for “opportunistic” screening. This…Abstract Number: 1997 • ACR Convergence 2025
Bone health in patients with gout using real-world U.S. data
Background/Purpose: Patients with gout may be at high risk for developing osteoporosis and fractures, but osteoporosis may be under-recognized and inadequately managed for gout patients.…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 23
- Next Page »